Validation of the patient benefit index for the assessment of patient-relevant benefit in the treatment of psoriasis

详细信息    查看全文

• 作者：Julia Feuerhahn (1) j.feuerhahn@uke.de
  Christine Blome (1)
  Marc Radtke (1)
  Matthias Augustin (1)
• 关键词：Psoriasis &#8211 ; Patient Benefit Index &#8211 ; Patient ; relevant benefit &#8211 ; Questionnaire &#8211 ; Patient ; reported outcomes
• 刊名：Archives of Dermatological Research
• 出版年：2012
• 出版时间：August 2012
• 年：2012
• 卷：304
• 期：6
• 页码：433-441
• 全文大小：423.2 KB
• 参考文献：1. Augustin M, Amon U, Braathen L, Bullinger M, Gieler U, Klein GF, Schultz-Amlung W (2004) Assessment of quality of life in dermatology. J Dtsch Dermtol Ges 2(9):802–806
  2. Augustin M, Blome C, Zschocke I, Sch盲fer I, Koenig S, Rustenbach SJ, Herberger K (2012) Benefit evaluation in the therapy of chronic wounds from the patients’ perspective: development and validation of a new method. Wound Rep Reg 20:8–14
  3. Augustin M, Gajur AI, Reich C, Rustenbach SJ, Schaefer I (2008) Benefit evaluation in vitiligo treatment: development and validation of a patient-defined outcome questionnaire. Dermatology 217:101–106
  4. Augustin M, Glaeske G, Radtke MA, Christophers E, Reich K, Sch盲fer I (2010) Epidemiology and comorbidity of psoriasis in children. Br J Dermatol 162(3):633–636
  5. Augustin M, Kr眉ger K, Radtke MA, Schwippl I, Reich K (2008) Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 216:366–372
  6. Augustin M, Radtke MA, Zschocke I, Blome C, Behechtnejad J, Sch盲fer I, Reusch M, Mielke V, Rustenbach SJ (2009) Patient benefit index: a novel approach in patient-defined outcomes measurement for skin disease. Arch Dermatol Res 301:561–571
  7. Augustin M, Radtke M (2008) Health economic issues in psoriasis. Expert Rev Dermatol 3(4):19–23
  8. Augustin M, Reich C, Schaefer I, Zschocke I, Rustenbach SJ (2008) Development and validation of a new instrument for the assessment of patient-defined benefit in the treatment of acne. J Dtsch Dermatol Ges 6:113–120
  9. Augustin M, Reich K, Glaeske G, Schaefer I, Radtke M (2010) Co-morbidity and age-related prevalence of psoriasis: analysis of health insurance data in Germany. Acta Derm Venereol 90(2):147–151
  10. Augustin M, Reich K, Reich C, Purwins S, Jeff Rustenbach S, Sch盲fer I, Radtke M (2008) Quality of psoriasis care in Germany-results of the national study PsoHealth 2007. J Dtsch Dermatol Ges 6(8):640–645
  11. Augustin M, Sch盲fer I, Rabini S, Lee-Seifert C, Radtke M, Rustenbach SJ (2009) Assessing the value of supportive skin care: development and validation of an instrument for evaluating patient-relevant benefit. Dermatology 218:255–259
  12. Berger K, Ehlken B, Kugland B, Augustin M (2005) Cost-of-illness in patients with moderate and severe chronic psoriasis vulgaris in Germany. JDDG 3:511–518
  13. Blome C, Augustin M, Behechtnejad J, Rustenbach SJ (2011) Dimensions of patients needs in dermatology: subscales of the patient benefit index. Arch Dermatol Res 303:11–17
  14. Blome C, Augustin M, Siepmann D, Phan NQ, Rustenbach SJ, St盲nder S (2009) Measuring patient-relevant benefits in pruritus treatment: development and validation of a specific outcomes tool. Br J Dermatol 161:1143–1148
  15. Blome C, Maares J, Diepgen T, Rustenbach SJ, Augustin M (2009) Measurement of patient-relevant benefits in the treatment of chronic hand eczema: a novel approach. Contact Dermatitis 61:39–45
  16. Blome C, Simianer S, Purwins S, Laas A, Rustenbach SJ, Schaefer I, Radtke M, Augustin M (2010) Time needed for treatment is the major predictor of quality of life in psoriasis. Dermatology 221:154–159
  17. Bowling A (1995) Measuring disease: a review of disease-specific quality of life measurement scales. Open University Press, Buckingham
  18. Brock D (1996) Quality of life measures in health care and medical ethics. In: Spilker B (ed) Quality of life and pharmacoeconomics in clinical trials. Lippincott-Raven, Philadelphia, pp 487–510
  19. Clark MS, Caudrey DJ (1983) Evaluation of rehabilitation services: the use of goal attainment scaling. Int Rehabil Med 5(1):41–45
  20. Dubertret L, Mrowietz U, Ranki A, van de Kerkhof PC, Chimenti S, Lotti T, Sch盲fer G, EUROPSO Patient Survey Group (2006) European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155:729–736
  21. Finlay AY, Khan GK (1994) Dermatology life quality index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 19(3):210–216
  22. Fisher K, Hardie RJ (2002) Goal attainment scaling in evaluating a multidisciplinary pain management programme. Clin Rehabil 16:871–877
  23. Franzke N, Sch盲fer I, Jost K, Blome C, Rustenbach SJ, Reich K, Reusch M, Maurer M, Augustin M (2011) A new instrument for the assessment of patient-defined benefit in the treatment of allergic rhinitis. Allergy 66:665–670
  24. Fredriksson T, Pettersson U (1978) Severe psoriasis: oral therapy with a new retinoid. Dermatologica 157(4):238–244
  25. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, Margolis DJ, Strom BL (2007) The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol 143:1493–1499
  26. Greaves MW, Weinstein GD (1995) Treatment of psoriasis. N Engl J Med 332:581–588
  27. Guyatt G, Walter S, Norman G (1987) Measuring change over time: assessing the usefulness of evaluative instruments. J Chron Dis 40:171–178
  28. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A (1997) Measuring health related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). Br J Rheumatol 36(5):551–559
  29. Kimball AB, Gieler U, Linder D, Sampogna F, Warren RB, Augustin M (2010) Psoriasis: is the impairment to a patient’s life cumulative? J Eur Acad Dermatol Venereol 24(9):989–1004
  30. Kiresuk T, Sherman R (1968) Goal attainment scaling: a general method for evaluating comprehensive community mental health programs. Community Ment Health J 4:443–453
  31. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T (2001) The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 137:280–284
  32. Lienert G, Raatz U (1998) Testaufbau und Testanalyse. Beltz, Weinheim
  33. Ottenbacher KJ, Cusick A (1990) Goal attainment scaling as a method of clinical service evaluation. Am J Occup Ther 44:519–525
  34. Radtke MA, Augustin M (2008) Economic considerations in psoriasis management. Clin Dermatol 26:424–431
  35. Rockwood K, Howlett S, Stadnyk K, Carver D, Powell C, Stolee P (2003) Responsiveness of goal attainment scaling in randomized controlled trial of comprehensive geriatric assessment. J Clin Epidemiol 56:736–743
  36. Rushton PW, Miller WC (2002) Goal attainment scaling in the rehabilitation of patients with lower-extremity amputations: a pilot study. Arch Phys Med Rehabil 83:771–775
  37. Schaefer I, Zimmer L, Rustenbach SJ, Augustin M (2008) Prevalence of skin diseases in a cohort of 48,665 employees in Germany. Dermatology 217:169–172
  38. Smith G (1988) Measuring health: a practical approach. Chichester, New York
  39. Sohn S, Schoeefski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M (2006) Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 212:137–144
  40. Steffanowski A, Lichtenberg S, Schmidt J, Huber C, Wittmann WW, N眉bling R (2004) Ergebnisqualit盲t psychosomatischer Rehabilitation: zielerreichungsskalierung auf der Basis einer strukturierten Therapiezielliste. Rehabilitation 43:219–232
  41. Steinbook RM, Jacobson AF, Mosher JC, Davies DL (1977) The goal attainment scale: an instructional guide for the delivery of social reinforcement. Arch Gen Psychiatry 34:923–926
  42. Stern RS, Nijsten T, Feldman SR, Margolis DJ, Rolstad T (2004) Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc 9:136–139
  43. Zentner A, Velasco-Garrido M, Busse R (2005) Methoden zur vergleichenden Bewertung pharmazeutischer Produkte. GMS Health Technol Assess (Internet). 2005 Nov 15 (cited 2009 Aug 19);1:Doc09(20051115). Available from: http://www.egms.de/dynamic/en/journals/hta/volume1.htm
  44. Zschocke I, Hammelmann U, Augustin M (2005) Therapeutischer Nutzen in der dermatologischen Behandlung. Hautarzt 56:839–846
  45. Zwingmann C (2003) Zielorientierte Ergebnismessung (ZOE) mit dem IHRES-Patientenfragebogen: eine kritische Zwischenbilanz. Rehabilitation 42:226–235
• 作者单位：1. Institute for Health Services Research in Dermatology and Nursing, CVderm-German Center for Health Services Research in Dermatology, University Clinics of Hamburg, Martinistrasse 52, 20246 Hamburg, Germany
• ISSN：1432-069X

文摘

Empirical evidence of the efficacy of drugs and therapeutic procedures becomes more important in industrial countries. The assessment of patient benefit from the patient’s perspective is of particular relevance. The Patient Benefit Index (PBI) for skin diseases is a validated instrument to assess patient-relevant benefit in patients with skin diseases. So far, no instrument for the assessment of patient-relevant needs and benefits in patients with psoriasis has been published. Objective of the study was the validation of an instrument to assess patient benefit in psoriasis treatment. Patient-relevant treatment needs and benefits in psoriasis patients were recorded with the PBI questionnaire in two studies conducted in 2007. Treatment goals and benefits were used to calculate an importance-weighted PBI. Data of n = 2,009 patients in the cross-sectional study and n = 93 patients in the longitudinal study were used to test validity, feasibility and reliability of the PBI. The PBI was feasible with a rate of missing values ≤1.5 % in PNQ and ≤2.0 % in PBQ. The subscales of the PBI were internally consistent (Cronbach’s alpha = 0.68–0.87). The PBI showed convergent validity regarding the quality of life, psoriasis area and severity index, and two single questions on treatment benefit used in the longitudinal study. The PBI is a suitable instrument for the assessment of patient-reported benefit in the treatment of psoriasis.